<SEC-DOCUMENT>0000947871-23-000670.txt : 20230612
<SEC-HEADER>0000947871-23-000670.hdr.sgml : 20230612
<ACCEPTANCE-DATETIME>20230612173233
ACCESSION NUMBER:		0000947871-23-000670
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230612
DATE AS OF CHANGE:		20230612

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Keros Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001664710
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811173868
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39264
		FILM NUMBER:		231009473

	BUSINESS ADDRESS:	
		STREET 1:		1050 WALTHAM STREET, SUITE 302
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-314-6297

	MAIL ADDRESS:	
		STREET 1:		1050 WALTHAM STREET, SUITE 302
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORBIMED CAPITAL LLC
		CENTRAL INDEX KEY:			0001157524
		IRS NUMBER:				134133323
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 739-6400

	MAIL ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED CAPITAL LLC -->
          <cik>0001157524</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001664710</issuerCik>
      <issuerName>Keros Therapeutics, Inc.</issuerName>
      <secFileNumber>001-39264</secFileNumber>
      <issuerAddress>
        <com:street1>1050 WALTHAM STREET, SUITE 302</com:street1>
        <com:city>LEXINGTON</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02421</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-314-6297</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>The Biotech Growth Trust PLC</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Evercore ISI</name>
        <address>
          <com:street1>55 East 52nd Street</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10055</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>170000</noOfUnitsSold>
      <aggregateMarketValue>7461300.00</aggregateMarketValue>
      <noOfUnitsOutstanding>29584173</noOfUnitsOutstanding>
      <approxSaleDate>06/12/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>03/02/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Private placement</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>170000</amountOfSecuritiesAcquired>
      <paymentDate>03/02/2020</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Capital LLC is the portfolio manager of The Biotech Growth Trust PLC.</remarks>
    <noticeSignature>
      <noticeDate>06/12/2023</noticeDate>
      <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Capital LLC, portfolio manager of The Biotech Growth Trust PLC</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
